证券代码：300003 证券简称：乐普医疗 公告编号：2025-085 债券代码：123108 债券简称：乐普转 2 乐普（北京）医疗器械股份有限公司 关于注销部分回购股份暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称：公司）于2025年9月10 日召开2025年第一次临时股东大会，审议通过《关于变更回购股份用途并注销 暨减少注册资本、修订公司章程》的议案，同意公司将在 2022年11月1日完成 回购的18,273,500股、2024年10月25日完成回购的18,942,200股回购股份用途 由"股权激励计划或员工持股计划"变更为"减少公司注册资本"，并授权公司 管理层办理回购股份注销的相关事宜。该部分回购股份注销完成后，公司总股本 将减少37,215,700股（最终的总股本变动情况以中国证券登记结算有限责任公司 深圳分公司登记的数据为准）。 根据《中华人民共和国公司法》等相关法律、法规的规定，公司特此通知债 权人，自本公告披露之日起四十五日内，公司债权人有权凭有效债权文件及相关 凭证要求公司清偿 ...

Core Viewpoint - Lepu Medical announced that from August 26, 2025, to September 8, 2025, its stock price has closed below 80% of the current conversion price (27.79 CNY/share), which is 22.23 CNY/share, indicating a potential trigger for the downward adjustment of the "Lepu Convertible Bond" conversion price [2][2][2] Summary by Relevant Sections - Company Announcement - Lepu Medical disclosed that it expects to trigger the condition for the downward adjustment of the conversion price of its convertible bonds due to the stock price performance [2][2][2] - Stock Performance - The company's stock has closed below the threshold of 22.23 CNY/share for 10 trading days, which is 80% of the current conversion price [2][2][2]

证券代码：300003 证券简称：乐普医疗 公告编号：2025-083 债券代码：123108 债券简称：乐普转 2 乐普（北京）医疗器械股份有限公司 一、可转债发行上市概况 关于预计触发"乐普转 2"转股价格向下修正条件的 提示性公告 （一）可转债发行上市基本情况 经中国证券监督管理委员会出具的《关于同意乐普（北京）医疗器械股份有 限公司向不特定对象发行可转换公司债券注册的批复》（证监许可[2021]741 号） 核准，公司于 2021 年 3 月 30 日向不特定对象发行了 1,638.00 万张可转换公司 债券，每张面值 100 元，发行总额 163,800.00 万元。 经深圳证券交易所同意，乐普医疗可转换公司债券于 2021 年 4 月 19 日起 在深圳证券交易所挂牌交易，债券简称"乐普转 2"，债券代码"123108"。转 股期自 2021 年 10 月 8 日至 2026 年 3 月 29 日。 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 5、自 2025 年 8 月 26 日至 2025 年 9 月 8 日，公司股票已有 ...

Core Viewpoint - Lepu Medical has announced the completion of the first dosing of the subject in the Phase II clinical trial of MWN105 injection, an innovative drug developed by its subsidiary, Shanghai Minwei Biotechnology Co., Ltd, aimed at treating overweight or obesity [1][2] Group 1: Clinical Trial Progress - MWN105 injection is a GLP-1/GIP/FGF21 receptor triple agonist with global intellectual property rights [1] - The Phase II clinical trial has been approved by the National Medical Products Administration, with the first subject successfully dosed [2] - The trial aims to evaluate the efficacy and safety of different doses of MWN105 injection over 24 weeks compared to a placebo in overweight or obese participants without diabetes [2] Group 2: Preclinical Results - Preclinical results in db/db mouse models show that MWN105 injection significantly reduces random blood glucose, fasting blood glucose, and glycated hemoglobin levels, while increasing the proportion of pancreatic β-cells and improving glucose tolerance [1] - In DIO obese mouse models, MWN105 injection significantly reduces body weight, fat content, and liver weight, as well as lowers food intake, low-density lipoprotein cholesterol (DL-C), total cholesterol (TC), and improves liver function [1] - In MASH mouse models, MWN105 injection significantly reduces body weight, liver weight, and liver-to-body ratio, while improving plasma ALT, AST, CHOL, LDL-C levels, and liver cholesterol and triglyceride content [1] Group 3: Safety and Efficacy - In spontaneous MASH monkeys with metabolic abnormalities, MWN105 injection reduces body weight and HbA1c levels, significantly lowers liver fat content, NAS scores, and inhibits the progression of liver fibrosis [2] - Safety evaluation trials indicate that MWN105 injection has good safety profiles [2]

Core Viewpoint - Lepu Medical has shown significant stock performance with a year-to-date increase of 63.10%, despite a recent decline of 3.84% over the last five trading days [1] Financial Performance - For the first half of 2025, Lepu Medical reported revenue of 3.369 billion yuan, a year-on-year decrease of 0.43%, and a net profit attributable to shareholders of 691 million yuan, down 0.91% year-on-year [2] - The company has distributed a total of 4.657 billion yuan in dividends since its A-share listing, with 1.758 billion yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Lepu Medical had 100,100 shareholders, an increase of 6.18% from the previous period, with an average of 16,152 circulating shares per shareholder, a decrease of 5.82% [2] - The top ten circulating shareholders include notable ETFs, with Hua Bao Zhong Zheng Medical ETF holding 43.7211 million shares, an increase of 701,700 shares from the previous period [3]

Group 1: Company Announcements - Heng Rui Medicine has received the clinical trial approval notice for HRS-4729 injection, a self-developed peptide drug targeting GLP-1R, GIPR, and GCGR receptors, with no similar products approved in the market [1] - Hubei Yihua has successfully launched its 200,000 tons/year caustic soda project, aimed at upgrading its chlor-alkali chemical industry and enhancing market competitiveness [2] - Ji Min Health announced that its shareholder, Shuangge Group, plans to reduce its stake by up to 3%, equating to a maximum of 15.75 million shares [3] - China Shipbuilding intends to absorb and merge with China Shipbuilding Industry Corporation through a share exchange, with the latter's A-shares set to be delisted on September 5, 2025 [4] - Changfei Fiber reported that its shareholder, Changjiang Communication, plans to reduce its stake by up to 0.15%, totaling no more than 1.1 million shares [5] Group 2: Strategic Collaborations and Developments - Beijing Lier has signed a strategic cooperation agreement with SenseTime and Xiwang Technology to explore AI computing power collaboration and related applications [6] - Junsheng Electronics is collaborating with leading clients like Zhiyuan Robotics, having achieved bulk supply of customized main control boards and various sensors [7][8] - Guoxin Technology has successfully tested a new generation of high-performance chips for automotive electronic BLDC motor control, aimed at addressing the MCU chip shortage in the automotive sector [9] Group 3: Other Corporate Actions - Guoguang Chain's actual controller plans to reduce their stake by up to 2.99%, totaling a maximum of 12.506 million shares [10] - Zhonghuan Hailu has terminated its control change plan, with its stock set to resume trading on September 5, 2025 [11] - Various companies have reported significant project wins, including Ningbo Construction winning contracts worth 1.117 billion yuan [12]

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]

Core Viewpoint - Lepu Medical announced that its subsidiary, Shanghai Minwei Biotechnology Co., Ltd., has initiated a Phase II clinical trial for its innovative drug MWN105 injection, aimed at treating overweight or obesity, successfully completing the first dosing of a subject [1] Group 1 - MWN105 injection is a triple agonist targeting GLP-1/GIP/FGF21 receptors, with global intellectual property rights [2] - Preclinical results indicate that MWN105 injection significantly reduces random blood glucose, fasting blood glucose, and glycated hemoglobin in db/db mouse models, while increasing the proportion of pancreatic β-cells and improving glucose tolerance [2] - In DIO obese mouse models, MWN105 injection shows significant reductions in body weight, fat content, and liver weight, as well as decreased food intake, low-density lipoprotein cholesterol (DL-C), total cholesterol (TC), and improved liver function [2] Group 2 - In the B6-A1ms1-de1 mouse MASH model, MWN105 injection significantly reduces body weight, liver weight, and liver-to-body ratio, while lowering plasma ALT, AST, CHOL, LDL-C levels, and liver CHOL and TG content, and significantly improving liver NAS scores [2] - In spontaneously MASH monkeys with metabolic disorders, MWN105 injection can reduce animal body weight and HbA1c levels, significantly lower liver fat content, liver NAS scores, and the proportion of liver fibrosis positivity, inhibiting the progression of liver fibrosis [2] - Safety evaluation tests indicate that MWN105 injection has good safety profiles [2]

Core Viewpoint - Lepu Medical (300003) announced that its subsidiary, Shanghai Minwei Biotechnology Co., Ltd., has initiated a Phase II clinical trial for its innovative drug MWN105 injection, aimed at treating overweight or obesity, with the first subject successfully dosed recently [1] Group 1 - The innovative drug MWN105 is being developed for the treatment of overweight or obesity [1] - The Phase II clinical trial has recently commenced with the successful dosing of the first participant [1]

证券代码：300003 证券简称：乐普医疗 公告编号：2025-082 MWN105 注射液是控股子公司民为生物自主研发的 GLP-1/GIP/FGF21 受 体三重激动剂，拥有全球知识产权。临床前结果显示，在 db/db 小鼠模型中， MWN105 注射液有明显的降低随机血糖、空腹血糖、糖化血红蛋白的作用，同 时具有增加 db/db 小鼠胰岛β细胞比重以及改善糖耐量受损的作用；在 DIO 肥 胖小鼠模型中，MWN105 注射液具有显著降低体重、脂肪含量和肝脏重量的作 用，同时能够降低小鼠摄食量、低密度脂蛋白胆固醇（DL-C）、总胆固醇（TC） 含量以及改善肝功能的作用；在 B6-A1ms1-de1 小鼠 MASH 模型中，MWN105 注射液可显著降低体重、肝重及肝体比，显著降低血浆 ALT、AST、CHOL、LDL-C 水平和肝脏 CHOL 和 TG 含量，同时能显著改善肝脏 NAS 评分（脂肪变性、气 球样变、炎症）。在自发 MASH 合并糖代谢异常恒河猴中，MWN105 注射液可 以降低动物体重、HbA1c 水平，同时能显著降低肝脏脂肪含量、肝脏 NAS 评分 以及肝纤维化阳性占比，抑制肝脏纤维化进展 ...